NCT00537121View on ClinicalTrials.gov

Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

June 30, 2013

Conditions

Esophageal CancerGastric CancerLiver Cancer

Interventions

DRUG

fluorouracil

Given IV

DRUG

irinotecan hydrochloride

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

vorinostat

Taken Orally

OTHER

pharmacological study

Correlative Study

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT00537121 - Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer | Biotech Hunter | Biotech Hunter